| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2013.06.062 |
| P698 | PubMed publication ID | 23827313 |
| P50 | author | Sumana Chandramouli | Q42872093 |
| Philip R Dormitzer | Q101423214 | ||
| P2093 | author name string | Pu Zhang | |
| Ethan C Settembre | |||
| Peter W Mason | |||
| Christian W Mandl | |||
| Luis A Brito | |||
| Angelica Medina-Selby | |||
| Doris Coit | |||
| Gillis Otten | |||
| Mary Schaefer | |||
| Terika Spencer | |||
| P2860 | cites work | Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention | Q26997377 |
| Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection | Q33373718 | ||
| Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence | Q33538033 | ||
| Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study | Q33548917 | ||
| A viral phospholipase A2 is required for parvovirus infectivity | Q34101246 | ||
| Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. | Q34179109 | ||
| Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface | Q34222176 | ||
| Parvovirus B19. | Q34294811 | ||
| Immune response to B19 parvovirus and an antibody defect in persistent viral infection | Q35815343 | ||
| An outbreak of erythema infectiosum associated with human parvovirus infection | Q36249646 | ||
| Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication | Q36483931 | ||
| Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea | Q38437347 | ||
| Development of an improved method of detection of infectious parvovirus B19. | Q40321434 | ||
| Epidemiology of human parvovirus B19 in children with sickle cell disease | Q40548961 | ||
| Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay | Q40974377 | ||
| Visualization of the externalized VP2 N termini of infectious human parvovirus B19. | Q41337979 | ||
| Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies. | Q41785165 | ||
| Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses | Q43001342 | ||
| Production and immunological analysis of recombinant hepatitis B vaccine | Q43941277 | ||
| Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). | Q45414037 | ||
| Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases | Q46346294 | ||
| Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses | Q47864425 | ||
| Risk factors for parvovirus B19 infection in pregnancy. | Q50643625 | ||
| Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy | Q69354191 | ||
| Candidate recombinant vaccine for human B19 parvovirus | Q70696649 | ||
| Characterization and Molecular Cloning of a Human Parvovirus Genome | Q72404065 | ||
| Congenital anaemia after transplacental B19 parvovirus infection | Q72673231 | ||
| Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors | Q81549480 | ||
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 3872-3878 | |
| P577 | publication date | 2013-07-02 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Generation of a parvovirus B19 vaccine candidate | |
| P478 | volume | 31 |
| Q92026959 | Advances in the Development of Antiviral Strategies against Parvovirus B19 |
| Q92387193 | Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development |
| Q36326644 | Generation of infectious recombinant Adeno-associated virus in Saccharomyces cerevisiae |
| Q40805602 | High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography |
| Q38996997 | Human Parvoviruses |
| Q55266915 | Immunogenicity evaluation of MS2 phage-mediated chimeric nanoparticle displaying an immunodominant B cell epitope of foot-and-mouth disease virus. |
| Q38423724 | Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles |
| Q40267316 | Porcine epidemic diarrhea virus virus-like particles produced in insect cells induce specific immune responses in mice |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q40181909 | Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease |
| Q40161791 | Strategies to optimize capsid protein expression and single-stranded DNA formation of adeno-associated virus in Saccharomyces cerevisiae |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q64089294 | Synthesis of 3-(Imidazo[2,1-]thiazol-6-yl)-2H-chromen-2-one Derivatives and Study of Their Antiviral Activity against Parvovirus B19 |
| Q36735626 | The Receptor-Binding Domain in the VP1u Region of Parvovirus B19. |
| Q37378794 | The VP1u Receptor Restricts Parvovirus B19 Uptake to Permissive Erythroid Cells. |
| Q38603912 | The application of virus-like particles as vaccines and biological vehicles |
| Q39012245 | Yeast as an expression system for producing virus-like particles: what factors do we need to consider? |
| Q40804758 | Yeast-generated virus-like particles as antigens for detection of human bocavirus 1-4 specific antibodies in human serum |
Search more.